Explore News By Topic

05/15/2018

VA Healthcare System Successfully Reduces ‘Rush to Treatment’ Rates for Low-Risk Prostate Cancer, Study Shows

May 15, 2018 - Record numbers of American veterans diagnosed with nonaggressive prostate cancer are heeding the advice of international medical experts and opting out of immediate surgery or radiation to treat their cancer. Instead, according to a study led by researchers at NYU School of Medicine, Perlmutter Cancer Center,... Read More

05/03/2018

PCF-funded investigators report progress on a promising new treatment for a highly lethal form of prostate cancer

Prostate cancer cells depend on androgens to grow and thrive.  Because of this dependency, hormone therapy – the blockade of androgens and the androgen receptor (AR) – has been the cornerstone of prostate cancer treatment for decades.  As science has progressed, therapies that are better and better at blocking these... Read More

2018 AACR-PCF Scholar-in-Training Award Recipients

Mark P. Labrecque, PhD University of Washington, Seattle, WA Abstract # 1092 Defining the molecular phenotypes of metastatic castration-resistant prostate cancer sensitive to FGF pathway inhibition M. P. Labrecque1, L. G. Brown1, I. M. Coleman2, L. D. True1, L. Kollath1, B. Lakely1, Y. C. Yang2, H. M. Nguyen1, E. Corey1,... Read More

04/03/2018

Actor and Comedian Chris Tucker Partners With The Prostate Cancer Foundation During National Minority Health Month to Create Awareness About the Increased Risks for African-American Men and Challenges Them to “Know the Numbers”

SANTA MONICA, Calif., April 3, 2018 -- The Prostate Cancer Foundation (PCF) announced today that actor, comedian and humanitarian Chris Tucker (Rush Hour) will join its National Minority Health Month initiative as a spokesperson to raise awareness about the significant disparities that exist between men of African descent and other ethnicities as well as... Read More

04/02/2018

Scientists uncover “long tail” of nearly 100 genes mutated in prostate cancer

APRIL 2, 2018 --  Issued by Dana-Farber Cancer Institute. By sequencing DNA in more than 1,000 patient samples, researchers have identified a total of 97 genes significantly mutated in prostate cancer, including 70 not previously implicated in the disease. The large-scale study identified a new class of prostate cancers defined... Read More

03/14/2018

New Study indicates 18 months of androgen deprivation therapy may be optimal for locally advanced prostate cancer

Results from the RADAR clinical trial presented at the 2018 ASCO Genitourinary Cancer Symposium indicate that 18 months of ADT could very likely become the new standard of care. The RADAR trial demonstrated that 18 months of androgen deprivation therapy (ADT) is significantly better than 6 months of ADT at... Read More

03/13/2018

Kristen Bell Chooses Winners of The Prostate Cancer Foundation’s 1st Annual TRUE Love Campaign Honoring Caregivers of Prostate Cancer Patients

SANTA MONICA, Calif., March 13, 2018 – The winners of the 1st Annual TRUE Love Campaign honoring caregivers of prostate cancer patients were announced today by the Prostate Cancer Foundation (PCF). Actress Kristen Bell selected the winning stories from hundreds of story submissions from people across the U.S., and the... Read More

02/27/2018

New NCCN Guidelines Incorporate PCF-Funded Research on Cancer Risk Genes

Thanks in large part to the kinds of genetic and precision medicine that the Prostate Cancer Foundation has been funding, the National Comprehensive Cancer Network (NCCN) has issued updated prostate cancer guidelines that include new information about the role of family history and genomic testing to select precision medicine treatments... Read More

02/15/2018

Prostate Cancer Loves Couch Potatoes

Hey, guys:  If you think exercise is just about pumping iron and getting big traps, six-pack abs and “gun show” biceps, your prostate would like to disagree. To your prostate, how ripped or shredded you are is not nearly as important as your cardiovascular health. Now, you may be wondering,... Read More

02/14/2018

BREAKING NEWS: FDA Approves Apalutamide (Erleada); the first treatment for non-metastatic castration-resistant prostate cancer

February 14, 2018 – Today the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada, also previously called ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC).  This clinical setting is when men who are being treated with androgen deprivation therapy (ADT) see their PSA levels begin to... Read More